• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

紫杉烷类在腹膜转移中的处置动力学。

Disposition kinetics of taxanes in peritoneal dissemination.

机构信息

Department of Pharmacy, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa 920-8641, Japan.

出版信息

Gastroenterol Res Pract. 2012;2012:963403. doi: 10.1155/2012/963403. Epub 2012 May 16.

DOI:10.1155/2012/963403
PMID:22666236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3362138/
Abstract

Treatment of cancers in the abdominal cavity, such as peritoneal dissemination, is difficult, but in principle intraperitoneal administration of anticancer drugs is expected to be preferable to systemic administration. Taxane anticancer drugs are used to treat gastric cancer patients with peritoneal dissemination. They are administered as micellar preparations, Taxol and Taxotere, which consist of paclitaxel in Cremophor EL (crEL) and docetaxel in Polysorbate-80 (PS-80), respectively. In this paper we review the disposition kinetics of taxane anticancer drugs after intraperitoneal administration in peritoneal dissemination patients and animal models and also discuss the effect of the surfactant vehicle on the behavior of taxanes.

摘要

腹腔内癌症的治疗，如腹膜转移，较为困难，但原则上腹腔内给予抗癌药物可能优于全身给予。紫杉醇类抗癌药物用于治疗有腹膜转移的胃癌患者。它们以胶束制剂紫杉醇（Taxol）和多西紫杉醇（Taxotere）的形式给予，分别由聚氧乙烯蓖麻油（crEL）中的紫杉醇和聚山梨醇酯 80（PS-80）中的多西紫杉醇组成。本文综述了在腹膜转移患者和动物模型中腹腔内给予紫杉醇类抗癌药物后的处置动力学，并讨论了表面活性剂载体对紫杉烷类药物行为的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/437c966bb82b/GRP2012-963403.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/6debff919126/GRP2012-963403.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/8f2ab8473b72/GRP2012-963403.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/83f47ae649ba/GRP2012-963403.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/f0b8ef169379/GRP2012-963403.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/53bbc480ebc4/GRP2012-963403.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/ca2117a7f38f/GRP2012-963403.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/0b4d9261fc51/GRP2012-963403.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/437c966bb82b/GRP2012-963403.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/6debff919126/GRP2012-963403.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/8f2ab8473b72/GRP2012-963403.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/83f47ae649ba/GRP2012-963403.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/f0b8ef169379/GRP2012-963403.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/53bbc480ebc4/GRP2012-963403.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/ca2117a7f38f/GRP2012-963403.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/0b4d9261fc51/GRP2012-963403.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d9c/3362138/437c966bb82b/GRP2012-963403.008.jpg

相似文献

1
Disposition kinetics of taxanes in peritoneal dissemination.紫杉烷类在腹膜转移中的处置动力学。
Gastroenterol Res Pract. 2012;2012:963403. doi: 10.1155/2012/963403. Epub 2012 May 16.
2
Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.紫杉醇在大鼠腹腔注射后的处置动力学及表面活性剂载体的影响。
J Pharm Pharmacol. 2004 May;56(5):629-34. doi: 10.1211/0022357023303.
3
Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.表面活性剂影响紫杉烷类在腹膜转移荷瘤大鼠中的分布。
Cancer Lett. 2010 Jan 28;287(2):182-6. doi: 10.1016/j.canlet.2009.06.018. Epub 2009 Jul 15.
4
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.聚氧乙烯蓖麻油对腹腔注射紫杉醇生物利用度的影响。
Clin Cancer Res. 2002 Apr;8(4):1237-41.
5
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.制剂载体的药理作用：对癌症化疗的影响
Clin Pharmacokinet. 2003;42(7):665-85. doi: 10.2165/00003088-200342070-00005.
6
Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination.腹腔内 NK105（一种用于腹腔转移的纳米胶束紫杉醇制剂）的抗肿瘤作用及药代动力学研究。
Cancer Sci. 2012 Jul;103(7):1304-10. doi: 10.1111/j.1349-7006.2012.02274.x. Epub 2012 Apr 19.
7
Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle--a new strategy against peritoneal dissemination of gastric cancer.以非动物稳定化透明质酸为载体腹腔内给药紫杉醇——一种对抗胃癌腹膜播散的新策略。
Cancer Lett. 2008 Dec 18;272(2):307-15. doi: 10.1016/j.canlet.2008.07.024. Epub 2008 Sep 2.
8
[The current situation and subjects of the intraperitoneal chemotherapy for peritoneal dissemination in gastric cancer].[胃癌腹膜播散的腹腔内化疗现状与课题]
Gan To Kagaku Ryoho. 2008 Jun;35(6):891-5.
9
Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.采用紫杉烷类药物进行腹腔内化疗治疗伴有腹膜播散的卵巢癌。
Eur J Surg Oncol. 2006 Aug;32(6):666-70. doi: 10.1016/j.ejso.2006.03.008. Epub 2006 Apr 17.
10
Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.紫杉烷脂质体对无胸腺裸鼠人卵巢肿瘤异种移植瘤的抗肿瘤疗效。
J Pharm Sci. 1995 Dec;84(12):1400-4. doi: 10.1002/jps.2600841204.

引用本文的文献

1
Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery.含胆汁酸的脂质纳米粒增强肝外 mRNA 递送。
Theranostics. 2024 Jan 1;14(1):1-16. doi: 10.7150/thno.89913. eCollection 2024.
2
Macromolecules in polysorbate 80 for injection: an important cause of anaphylactoid reactions.注射用聚山梨酯 80 中的大分子物质：引起过敏样反应的重要原因。
BMC Pharmacol Toxicol. 2022 Jul 18;23(1):52. doi: 10.1186/s40360-022-00591-5.
3
Complete pathological response of high grade appendicular neoplasm induced Pseudomyxoma Peritonei (PMP) after neoadjuvant intra-peritoneal chemotherapy: A case report.

本文引用的文献

1
Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.表面活性剂影响紫杉烷类在腹膜转移荷瘤大鼠中的分布。
Cancer Lett. 2010 Jan 28;287(2):182-6. doi: 10.1016/j.canlet.2009.06.018. Epub 2009 Jul 15.
2
Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study.每周腹腔注射多西他赛治疗晚期胃癌伴腹膜转移患者的双重抗癌作用：一项可行性和药代动力学研究。
Oncol Rep. 2008 May;19(5):1305-10.
3
Cremophor EL releases cyclosporin A adsorbed on blood cells and blood vessels, and increases apparent plasma concentration of cyclosporin A.
新辅助腹腔化疗后高级别阑尾肿瘤诱发腹膜假黏液瘤（PMP）的完全病理缓解：一例报告
Int J Surg Case Rep. 2020;72:117-121. doi: 10.1016/j.ijscr.2020.05.072. Epub 2020 Jun 6.
4
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).细胞减灭术和腹腔热灌注化疗与姑息性全身化疗治疗胃癌伴腹膜转移患者的比较：一项多中心随机对照试验（PERISCOPE II）研究方案。
BMC Cancer. 2019 May 6;19(1):420. doi: 10.1186/s12885-019-5640-2.
5
Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study.胃癌患者腹膜播散的细胞减灭术和腹腔内热灌注化疗（HIPEC）治疗：PERISCOPE研究的原理与设计
JMIR Res Protoc. 2017 Jul 13;6(7):e136. doi: 10.2196/resprot.7790.
聚氧乙烯蓖麻油（Cremophor EL）可释放吸附在血细胞和血管上的环孢素A，并提高环孢素A的表观血浆浓度。
Int J Pharm. 2005 Apr 11;293(1-2):137-44. doi: 10.1016/j.ijpharm.2004.12.023.
4
Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice.腹腔注射多西他赛治疗小鼠腹膜癌转移的药代动力学优势
J Pharm Pharmacol. 2005 Feb;57(2):177-81. doi: 10.1211/0022357055380.
5
Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy.围手术期腹腔内化疗所用化疗药物的最新进展。
Oncologist. 2005 Feb;10(2):112-22. doi: 10.1634/theoncologist.10-2-112.
6
Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer.腹腔注射多西他赛对胃癌腹膜播散的影响。
Cancer Lett. 2004 Jul 16;210(2):189-96. doi: 10.1016/j.canlet.2004.03.018.
7
Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.紫杉醇在大鼠腹腔注射后的处置动力学及表面活性剂载体的影响。
J Pharm Pharmacol. 2004 May;56(5):629-34. doi: 10.1211/0022357023303.
8
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.腹腔内多西他赛治疗主要局限于腹腔的晚期恶性肿瘤的I期试验：剂量限制性毒性和药代动力学。
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5896-901.
9
Intraperitoneal taxanes.腹腔内紫杉烷类药物
Surg Oncol Clin N Am. 2003 Jul;12(3):825-33. doi: 10.1016/s1055-3207(03)00038-3.
10
Effective therapy for peritoneal dissemination in gastric cancer.胃癌腹膜播散的有效治疗方法。
Surg Oncol Clin N Am. 2003 Jul;12(3):635-48. doi: 10.1016/s1055-3207(03)00035-8.